Peptides DB
Research-centric peptide and protocol reference hub

Retatrutide (LY3437943) record · updated 16h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 34 studiesJump to the evidenceCompare
What is Retatrutide (LY3437943) used for?

Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes

How it works: Triple GLP-1 / GIP / glucagon receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Retatrutide (LY3437943) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 35 registered trials. It describes the research record, not a recommendation.

Identity
NameRetatrutide (LY3437943)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMetabolic
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
MechanismTriple GLP-1 / GIP / glucagon receptor agonist
RouteSubcutaneous injection
Half-life~6 days
Time to peak—
DurationWeekly dosing (investigational)
Extraction confidence0.75
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 29, 2026. How this works →
Research stats
Total studies34
Human / animal / cellular10 / 4 / 0
Highest trial phasePhase 3
Years covered2023–2026
Latest study9d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

34 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.
TakeawayGLP-1 receptor agonists show promise in managing type 2 diabetes and obesity, but their long-term safety and effectiveness require ongoing evaluation.
review2026Full text read0.70
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.
Finding-34.3 events/hour AHI change with 9 mg retatrutide vs -9.9 with placebo in TRIUMPH-1-OSA, difference vs placebo -24.4 (95% CI, -34.1 to -14.7)
Human2026Full text read0.85
Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
TakeawayNot reported in abstract.
—2026Title only0.10
Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
TakeawayNot reported in abstract.
—2026Title only0.10
Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
TakeawayNot reported in abstract.
—2026Title only0.10
Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
TakeawayNot reported in abstract.
—2026Title only0.10
The First Triple Agonist for Antiobesity: Retatrutide.
FindingNot reported in abstract.
review2024Partial text0.60
The First Triple Agonist for Antiobesity: Retatrutide.
FindingNot reported in abstract.
review2026Partial text0.50
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Finding-18.8% bodyweight change at week 80 with retatrutide 12 mg, n=287, p<0.0001.
Human2026Full text read0.90
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Finding-25.0% mean percent change in body weight for 12 mg dose vs -3.9% placebo, P<0.001
Human2026Full text read0.90
Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
TakeawayNot reported in abstract.
—2026Title only0.10
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.
FindingTotal weight loss of 58.8% (-108.7 kg) at 18 months.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Retatrutide (LY3437943) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Retatrutide (LY3437943) is discussed should be drawn from it.

Articles mentioning Retatrutide (LY3437943)